← All trials
NCT02660242
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2016
- Primary completion
- Feb 15, 2017
- Completion date
- Feb 15, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 15
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Jaeb Center for Health ResearchLead sponsor
- Jaeb Center for Health ResearchOverall official - principal investigator
- York UniversityStudy chair
- University of PennsylvaniaStudy chair
- Joslin Diabetes CenterStudy chair
- Xeris PharmaceuticalsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.